{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:20Z","timestamp":1793228240015,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Support from human genetics increases the probability of success in drug development. However, few examples exist of successful genomically-driven drug repositioning. Given that a Mendelian form of severe enterocolitis is due to up-regulation of the interleukin-18 (IL18) signaling pathway, and pharmacologic inhibition of IL18 has been shown to reverse this enterocolitis, we undertook a Mendelian randomization study to test the causal effect of elevated IL18 levels on inflammatory bowel disease susceptibility (IBD) in 12,882 cases and 21,770 controls. Mendelian randomization is an established method to assess the role of biomarkers in disease etiology in a manner that minimizes confounding and prevents reverse causation. Using three SNPs that explained almost 7% of the variance in IL18 level, we found that each genetically predicted standard deviation increase in IL18 was associated with an increase in IBD susceptibility (odds ratio\u2009=\u20091.22, 95% CI\u2009=\u20091.11\u20131.34, P-value\u2009=\u20096\u2009\u00d7\u200910\n                    <jats:sup>\u22125<\/jats:sup>\n                    ). This association was further validated in 25,042 IBD cases and 34,915 controls (odds ratio\u2009=\u20091.13, 95% CI\u2009=\u20091.05\u20131.20). Recently, an anti-IL18 monoclonal antibody, which decreased free IL18 levels, was found to be safe, yet ineffective in a phase II trial for type 2 diabetes. Taken together, these genomic findings implicated IBD as an alternative indication for anti-IL18 therapy, which should be tested in randomized controlled trials.\n                  <\/jats:p>","DOI":"10.1038\/s41598-019-45747-2","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T06:03:14Z","timestamp":1561701794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Interleukin-18 as a drug repositioning opportunity for inflammatory bowel disease: A Mendelian randomization study"],"prefix":"10.1038","volume":"9","author":[{"given":"Lauren E.","family":"Mokry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Devey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Langenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Wareham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Waterworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lon","family":"Cardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Sanseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Davey Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3746-9086","authenticated-orcid":false,"given":"J. Brent","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,28]]},"reference":[{"key":"45747_CR1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nrd4090","volume":"12","author":"J Arrowsmith","year":"2013","unstructured":"Arrowsmith, J. & Miller, P. Trial watch: phase II and phase III attrition rates 2011\u20132012. Nat. Rev. Drug Discov. 12, 569 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"45747_CR2","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/nrd.2016.184","volume":"15","author":"RK Harrison","year":"2016","unstructured":"Harrison, R. K. Phase II and phase III failures: 2013\u20132015. Nat. Rev. Drug Discov. 15, 817\u2013818 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"45747_CR3","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nrg3315","volume":"13","author":"J Brent Richards","year":"2012","unstructured":"Brent Richards, J. et al. Genetics of osteoporosis from genome-wide association studies: advances and challenges. Nat. Rev. Genet. 13, 672\u2013672 (2012).","journal-title":"Nat. Rev. Genet."},{"key":"45747_CR4","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3314","volume":"47","author":"MR Nelson","year":"2015","unstructured":"Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856\u2013860 (2015).","journal-title":"Nat. Genet."},{"key":"45747_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","volume":"491","author":"L Jostins","year":"2012","unstructured":"Jostins, L. et al. Host{\\textendash}microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119\u2013124 (2012).","journal-title":"Nature"},{"key":"45747_CR6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/ng.3359","volume":"47","author":"JZ Liu","year":"2015","unstructured":"Liu, J. Z. et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat. Genet. 47, 979\u201386 (2015).","journal-title":"Nat. Genet."},{"key":"45747_CR7","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/j.1365-2036.2011.04599.x","volume":"33","author":"L Peyrin-Biroulet","year":"2011","unstructured":"Peyrin-Biroulet, L. & L\u00e9mann, M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment. Pharmacol. Ther 33, 870\u20139 (2011).","journal-title":"Aliment. Pharmacol. Ther"},{"key":"45747_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fimmu.2013.00181","volume":"4","author":"LR Lopetuso","year":"2013","unstructured":"Lopetuso, L. R., Chowdhry, S. & Pizarro, T. T. Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease. Front. Immunol. 4, 181 (2013).","journal-title":"Front. Immunol."},{"key":"45747_CR9","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/ng.3089","volume":"46","author":"SW Canna","year":"2014","unstructured":"Canna, S. W. et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat. Genet. 46, 1140\u20136 (2014).","journal-title":"Nat. Genet."},{"key":"45747_CR10","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/ng.3066","volume":"46","author":"N Romberg","year":"2014","unstructured":"Romberg, N. et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat. Genet. 46, 1135\u20131139 (2014).","journal-title":"Nat. Genet."},{"key":"45747_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.10.022","author":"SW Canna","year":"2016","unstructured":"Canna, S. W. et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J. Allergy Clin. Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2016.10.022 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"45747_CR12","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.4049\/jimmunol.162.11.6829","volume":"162","author":"TT Pizarro","year":"1999","unstructured":"Pizarro, T. T. et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn\u2019s disease: expression and localization in intestinal mucosal cells. J. Immunol. 162, 6829\u201335 (1999).","journal-title":"J. Immunol."},{"key":"45747_CR13","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.cell.2015.10.072","volume":"163","author":"R Nowarski","year":"2015","unstructured":"Nowarski, R. et al. Epithelial IL-18 Equilibrium Controls Barrier Function in Colitis. Cell 163, 1444\u201356 (2015).","journal-title":"Cell"},{"key":"45747_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ije\/dyg070","volume":"32","author":"GD Smith","year":"2003","unstructured":"Smith, G. D. & Ebrahim, S. \u2018Mendelian randomization\u2019: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32, 1\u201322 (2003).","journal-title":"Int J Epidemiol"},{"key":"45747_CR15","doi-asserted-by":"publisher","first-page":"e0150018","DOI":"10.1371\/journal.pone.0150018","volume":"11","author":"EA McKie","year":"2016","unstructured":"McKie, E. A. et al. A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes Mellitus. PLoS One 11, e0150018 (2016).","journal-title":"PLoS One"},{"key":"45747_CR16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/gepi.21758","volume":"37","author":"S Burgess","year":"2013","unstructured":"Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet. Epidemiol. 37, 658\u2013665 (2013).","journal-title":"Genet. Epidemiol."},{"key":"45747_CR17","doi-asserted-by":"publisher","unstructured":"Ahola-Olli, A. et al. Genome-wide association study identifies 17 new loci influencing concentrations of circulating cytokines and growth factors. bioRxiv 045005, https:\/\/doi.org\/10.1101\/045005 (2016).","DOI":"10.1101\/045005"},{"key":"45747_CR18","doi-asserted-by":"publisher","first-page":"e1006706","DOI":"10.1371\/journal.pgen.1006706","volume":"13","author":"L Folkersen","year":"2017","unstructured":"Folkersen, L. et al. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. PLoS Genet. 13, e1006706 (2017).","journal-title":"PLoS Genet."},{"issue":"2","key":"45747_CR19","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/ng.3760","volume":"49","author":"Katrina M de Lange","year":"2017","unstructured":"De Lange, K. M. et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat. Genet., https:\/\/doi.org\/10.1038\/ng.3760 (2017).","journal-title":"Nature Genetics"},{"key":"45747_CR20","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/ng.3755","volume":"49","author":"JC Lee","year":"2017","unstructured":"Lee, J. C. et al. Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn\u2019s disease. Nat. Genet. 49, 262\u2013268 (2017).","journal-title":"Nat. Genet."},{"key":"45747_CR21","doi-asserted-by":"publisher","first-page":"e1001866","DOI":"10.1371\/journal.pmed.1001866","volume":"12","author":"LE Mokry","year":"2015","unstructured":"Mokry, L. E. et al. Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLoS Med. 12, e1001866 (2015).","journal-title":"PLoS Med."},{"key":"45747_CR22","doi-asserted-by":"publisher","first-page":"e1002607","DOI":"10.1371\/journal.pgen.1002607","volume":"8","author":"Z Dastani","year":"2012","unstructured":"Dastani, Z. et al. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet. 8, e1002607 (2012).","journal-title":"PLoS Genet."},{"key":"45747_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin Trials 7, 177\u2013188 (1986).","journal-title":"Control Clin Trials"},{"key":"45747_CR24","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1093\/ije\/dyn065","volume":"37","author":"NA Patsopoulos","year":"2008","unstructured":"Patsopoulos, N. A., Evangelou, E. & Ioannidis, J. P. A. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int. J. Epidemiol 37, 1148\u201357 (2008).","journal-title":"Int. J. Epidemiol"},{"key":"45747_CR25","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jama.2016.14568","volume":"316","author":"LA Lotta","year":"2016","unstructured":"Lotta, L. A. et al. Association Between Low-Density Lipoprotein Cholesterol\u2013Lowering Genetic Variants and Risk of Type 2 Diabetes. JAMA 316, 1383 (2016).","journal-title":"JAMA"},{"key":"45747_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","volume":"491","author":"L Jostins","year":"2012","unstructured":"Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119\u201324 (2012).","journal-title":"Nature"},{"key":"45747_CR27","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/ng.764","volume":"43","author":"CA Anderson","year":"2011","unstructured":"Anderson, C. A. et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat. Genet. 43, 246\u201352 (2011).","journal-title":"Nat. Genet."},{"key":"45747_CR28","first-page":"1118","volume":"42","author":"A Franke","year":"2010","unstructured":"Franke, A. et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn\u2019s disease susceptibility loci. Nat. Publ. Gr 42, 1118\u20131125 (2010).","journal-title":"Nat. Publ. Gr"},{"key":"45747_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","volume":"489","author":"TE Project","year":"2012","unstructured":"Project, T. E. et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57\u201374 (2012).","journal-title":"Nature"},{"key":"45747_CR30","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/nbt1010-1045","volume":"28","author":"BE Bernstein","year":"2010","unstructured":"Bernstein, B. E. et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat. Biotechnol. 28, 1045\u20138 (2010).","journal-title":"Nat. Biotechnol."},{"key":"45747_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2217\/epi.12.18","volume":"4","author":"LH Chadwick","year":"2012","unstructured":"Chadwick, L. H. The NIH Roadmap Epigenomics Program data resource. Epigenomics 4, 317\u2013324 (2012).","journal-title":"Epigenomics"},{"key":"45747_CR32","doi-asserted-by":"crossref","unstructured":"GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580\u20135 (2013).","DOI":"10.1038\/ng.2653"},{"key":"45747_CR33","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1101\/gr.229102","volume":"12","author":"WJ Kent","year":"2002","unstructured":"Kent, W. J. et al. The human genome browser at UCSC. Genome Res. 12, 996\u20131006 (2002).","journal-title":"Genome Res."},{"key":"45747_CR34","doi-asserted-by":"publisher","first-page":"D717","DOI":"10.1093\/nar\/gkv1275","volume":"44","author":"ML Speir","year":"2016","unstructured":"Speir, M. L. et al. The UCSC Genome Browser database: 2016 update. Nucleic Acids Res 44, D717\u2013D725 (2016).","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"45747_CR35","doi-asserted-by":"publisher","first-page":"e1004383","DOI":"10.1371\/journal.pgen.1004383","volume":"10","author":"Claudia Giambartolomei","year":"2014","unstructured":"Giambartolomei, C. et al. Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. PLoS Genet. 10 (2014).","journal-title":"PLoS Genetics"},{"key":"45747_CR36","doi-asserted-by":"publisher","first-page":"e34408","DOI":"10.7554\/eLife.34408","volume":"7","author":"G Hemani","year":"2018","unstructured":"Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 7, e34408 (2018).","journal-title":"Elife"},{"key":"45747_CR37","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.it.2015.06.002","volume":"36","author":"ME Sellin","year":"2015","unstructured":"Sellin, M. E., Maslowski, K. M., Maloy, K. J. & Hardt, W.-D. Inflammasomes of the intestinal epithelium. Trends Immunol. 36, 442\u201350 (2015).","journal-title":"Trends Immunol."},{"key":"45747_CR38","unstructured":"GTEx Portal: https:\/\/gtexportal.org\/home\/."},{"key":"45747_CR39","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1083\/jcb.123.6.1777","volume":"123","author":"M Furuse","year":"1993","unstructured":"Furuse, M. et al. Occludin: a novel integral membrane protein localizing at tight junctions. J. Cell Biol. 123, 1777\u201388 (1993).","journal-title":"J. Cell Biol."},{"key":"45747_CR40","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/ije\/dyt179","volume":"42","author":"M-JJA Brion","year":"2013","unstructured":"Brion, M.-J. J. A., Shakhbazov, K. & Visscher, P. M. Calculating statistical power in Mendelian randomization studies. Int. J. Epidemiol 42, 1497\u20131501 (2013).","journal-title":"Int. J. Epidemiol"},{"key":"45747_CR41","first-page":"289","volume":"4","author":"CA Dinarello","year":"2013","unstructured":"Dinarello, C. A., Novick, D., Kim, S. & Kaplanski, G. Interleukin-18 and IL-18 Binding Protein. Front. Immunol. 4, 289 (2013).","journal-title":"Front. Immunol."},{"key":"45747_CR42","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/jama.2016.21189","volume":"317","author":"G Davey Smith","year":"2017","unstructured":"Davey Smith, G., Paternoster, L. & Relton, C. When Will Mendelian Randomization Become Relevant for Clinical Practice and Public Health? Jama 317, 589 (2017).","journal-title":"Jama"},{"key":"45747_CR43","unstructured":"Munafo, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider Scope: How selection bias can induce spurious associations. bioRxiv (2016)."},{"key":"45747_CR44","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s00125-008-1160-3","volume":"51","author":"S Rafiq","year":"2008","unstructured":"Rafiq, S. et al. Gene variants influencing measures of inflammation or predisposing to autoimmune and inflammatory diseases are not associated with the risk of type 2 diabetes. Diabetologia 51, 2205\u20132213 (2008).","journal-title":"Diabetologia"},{"key":"45747_CR45","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1093\/bioinformatics\/btw373","volume":"32","author":"JR Staley","year":"2016","unstructured":"Staley, J. R. et al. PhenoScanner: a database of human genotype\u2013phenotype associations. Bioinformatics 32, 3207\u20133209 (2016).","journal-title":"Bioinformatics"},{"key":"45747_CR46","doi-asserted-by":"crossref","unstructured":"Molodecky, N. A. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46\u201354.e42; quiz e30 (2012).","DOI":"10.1053\/j.gastro.2011.10.001"},{"key":"45747_CR47","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/ajg.2011.71","volume":"106","author":"AC Ford","year":"2011","unstructured":"Ford, A. C. et al. Efficacy of 5-aminosalicylates in Crohn\u2019s disease: systematic review and meta-analysis. Am. J. Gastroenterol. 106, 617\u201329 (2011).","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"45747_CR48","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/ajg.2011.73","volume":"106","author":"Alexander C Ford","year":"2011","unstructured":"Ford, A. C. et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am. J. Gastroenterol. 106, 644\u201359, quiz 660 (2011).","journal-title":"American Journal of Gastroenterology"},{"key":"45747_CR49","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1365-2036.1995.tb00384.x","volume":"9","author":"JK Marshall","year":"1995","unstructured":"Marshall, J. K. & Irvine, E. J. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment. Pharmacol. Ther 9, 293\u2013300 (1995).","journal-title":"Aliment. Pharmacol. Ther"},{"key":"45747_CR50","unstructured":"ClinicalTrials.Gov: https:\/\/clinicaltrials.gov\/."},{"key":"45747_CR51","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","volume":"7","author":"J Burisch","year":"2013","unstructured":"Burisch, J., Jess, T., Martinato, M. & Lakatos, P. L. & ECCO -EpiCom. The burden of inflammatory bowel disease in. Europe. J. Crohn\u2019s Colitis 7, 322\u2013337 (2013).","journal-title":"Europe. J. Crohn\u2019s Colitis"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45747-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45747-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45747-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T17:00:01Z","timestamp":1694970001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45747-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,28]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["45747"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-45747-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,28]]},"assertion":[{"value":"13 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.A.S., L.D., D.W., L.C. and P.S. were employed by GlaxoSmtihKline at the time of manuscript preparation and submission. L.D. was employed by Celgene at the time of manuscript resubmission. This did not influence findings or the interpretation of results. J.B.R.\u2019s affiliated research institute has received funding from GlaxoSmithKline to explore drug repositioning opportunities. The remaining authors declare that no competing interests exist.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9386"}}